UTHR

SEC source: 0001415889-22-008276 · form4-08042022_030815.xml · nonDerivative · entry 1

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,949

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

SEC source: 0001415889-22-007915 · form4-07222022_040709.xml · derivative · entry 6

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,552

Underlying: Common Stock · 6,000 shares

Expires 2028-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

SEC source: 0001415889-22-007915 · form4-07222022_040709.xml · nonDerivative · entry 5

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,397

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $227.2650 to $227.885. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-007915 · form4-07222022_040709.xml · nonDerivative · entry 4

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,897

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $226.18 to $227.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-007915 · form4-07222022_040709.xml · nonDerivative · entry 3

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,197

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $225.11 to $226.045. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-007915 · form4-07222022_040709.xml · nonDerivative · entry 2

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,997

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $224.10 to $225.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-007915 · form4-07222022_040709.xml · nonDerivative · entry 1

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,397

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

SEC source: 0001415889-22-007625 · form4-07112022_040701.xml · nonDerivative · entry 2

DWEK RAYMOND · CIK 0001231617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: This sale of common stock was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

SEC source: 0001415889-22-007606 · form4-07082022_020701.xml · derivative · entry 2

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,230 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007606 · form4-07082022_020701.xml · nonDerivative · entry 1

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007610 · form4-07082022_020736.xml · derivative · entry 2

Giltner Richard · CIK 0001460472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,160 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007610 · form4-07082022_020736.xml · nonDerivative · entry 1

Giltner Richard · CIK 0001460472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,870

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007608 · form4-07082022_020737.xml · derivative · entry 2

Klein Katherine J · CIK 0001625073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007608 · form4-07082022_020737.xml · nonDerivative · entry 1

Klein Katherine J · CIK 0001625073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007607 · form4-07082022_020719.xml · derivative · entry 2

CAUSEY CHRISTOPHER · CIK 0001237334 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,160 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007607 · form4-07082022_020719.xml · nonDerivative · entry 1

CAUSEY CHRISTOPHER · CIK 0001237334 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,835

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007604 · form4-07082022_020730.xml · derivative · entry 1

PATUSKY CHRISTOPHER · CIK 0001231427 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,980

Underlying: Common Stock · 4,980 shares

Expires 2032-07-07

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007602 · form4-07082022_020747.xml · derivative · entry 2

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,230 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007602 · form4-07082022_020747.xml · nonDerivative · entry 1

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,330

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock

SEC source: 0001415889-22-007600 · form4-07082022_020726.xml · derivative · entry 2

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,160 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007600 · form4-07082022_020726.xml · nonDerivative · entry 1

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,390

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007601 · form4-07082022_020744.xml · derivative · entry 4

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007601 · form4-07082022_020744.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007627 · form4a-07112022_040712.xml · derivative · entry 2

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock).

F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F4 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007627 · form4a-07112022_040712.xml · nonDerivative · entry 1

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock).

F2 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007628 · form4a-07112022_040717.xml · derivative · entry 2

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock).

F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F4 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007628 · form4a-07112022_040717.xml · nonDerivative · entry 1

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This amendment corrects an overstatement of the number of restricted stock units that vested on July 8, 2022, and the number of resulting shares of common stock received by the reporting person. In both cases, the original number reported (3,230 restricted stock units / shares of common stock) has been corrected (1,080 restricted stock units / shares of common stock).

F2 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007626 · form4a-07112022_040706.xml · derivative · entry 2

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · shares: This amendment corrects an error in the original filing, which incorrectly listed these restricted stock units as "Acquired" instead of "Disposed of".

F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F4 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007626 · form4a-07112022_040706.xml · nonDerivative · entry 1

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007625 · form4-07112022_040701.xml · derivative · entry 3

DWEK RAYMOND · CIK 0001231617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,160 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F4 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007625 · form4-07112022_040701.xml · nonDerivative · entry 1

DWEK RAYMOND · CIK 0001231617 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on July 8, 2022. Restricted stock units converted on a one-for-one basis into shares of common stock.

SEC source: 0001415889-22-007606 · form4-07082022_020701.xml · derivative · entry 4

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,490

Underlying: Common Stock · 2,490 shares

Expires 2032-07-07

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007606 · form4-07082022_020701.xml · derivative · entry 3

KURZWEIL RAY · CIK 0001108501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 880 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007610 · form4-07082022_020736.xml · derivative · entry 3

Giltner Richard · CIK 0001460472 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007608 · form4-07082022_020737.xml · derivative · entry 4

Klein Katherine J · CIK 0001625073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,490

Underlying: Common Stock · 2,490 shares

Expires 2032-07-07

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007608 · form4-07082022_020737.xml · derivative · entry 3

Klein Katherine J · CIK 0001625073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 880 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · derivative · entry 4

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,490

Underlying: Common Stock · 2,490 shares

Expires 2032-07-07

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007609 · form4-07082022_020734.xml · derivative · entry 3

Mesa Nilda · CIK 0001756697 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 880 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007607 · form4-07082022_020719.xml · derivative · entry 3

CAUSEY CHRISTOPHER · CIK 0001237334 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007605 · form4-07082022_020752.xml · derivative · entry 1

MAXWELL LINDA · CIK 0001822674 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,980

Underlying: Common Stock · 4,980 shares

Expires 2032-07-07

F1 · shares: Annual non-employee director award.

F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007602 · form4-07082022_020747.xml · derivative · entry 4

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,490

Underlying: Common Stock · 2,490 shares

Expires 2032-07-07

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007602 · form4-07082022_020747.xml · derivative · entry 3

SULLIVAN LOUIS W · CIK 0001193522 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 880 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007600 · form4-07082022_020726.xml · derivative · entry 3

Olian Judy D. · CIK 0001605729 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,750

Underlying: Common Stock · 1,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007601 · form4-07082022_020744.xml · derivative · entry 6

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,980

Underlying: Common Stock · 2,490 shares

Expires 2032-07-07

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007601 · form4-07082022_020744.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 880 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F5 · derivative.exercise_date: The reporting person has elected to defer receipt of the shares upon conversion of t his award until on or about July 7, 2024.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

SEC source: 0001415889-22-007576 · form4-07082022_040701.xml · derivative · entry 6

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,552

Underlying: Common Stock · 6,000 shares

Expires 2028-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

SEC source: 0001415889-22-007576 · form4-07082022_040701.xml · nonDerivative · entry 5

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,397

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $243.60 to $243.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001415889-22-007576 · form4-07082022_040701.xml · nonDerivative · entry 4

MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,097

F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $242.365 to $243.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.